image credit: Pxhere

USFDA issues warning letter to Cipla for Goa manufacturing facility

February 26, 2020

Drug firm Cipla LtdNSE -4.53 % on Wednesday said that the US health regulator has issued a warning letter to the company for its manufacturing facility in Goa.

“Further to our earlier communication on the Goa manufacturing facility inspection conducted from September 16-27, 2019 by the United States Food and Drug Administration (USFDA), the company has received a warning letter from USFDA,” Cipla Ltd said in a regulatory filing.

Read More on The Economic Times